ACHV vs. XOMA, VNDA, VSTM, CDXS, SGMO, AGEN, IRWD, DOMH, FBIO, and CRIS
Should you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Codexis (CDXS), Sangamo Therapeutics (SGMO), Agenus (AGEN), Ironwood Pharmaceuticals (IRWD), Dominari (DOMH), Fortress Biotech (FBIO), and Curis (CRIS). These companies are all part of the "biotechnology" industry.
Achieve Life Sciences vs. Its Competitors
XOMA Royalty (NASDAQ:XOMA) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.
XOMA Royalty currently has a consensus target price of $69.50, suggesting a potential upside of 162.92%. Achieve Life Sciences has a consensus target price of $14.33, suggesting a potential upside of 551.52%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Achieve Life Sciences is more favorable than XOMA Royalty.
In the previous week, Achieve Life Sciences had 1 more articles in the media than XOMA Royalty. MarketBeat recorded 3 mentions for Achieve Life Sciences and 2 mentions for XOMA Royalty. XOMA Royalty's average media sentiment score of 0.23 beat Achieve Life Sciences' score of 0.11 indicating that XOMA Royalty is being referred to more favorably in the media.
XOMA Royalty has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
Achieve Life Sciences has a net margin of 0.00% compared to XOMA Royalty's net margin of -13.04%. XOMA Royalty's return on equity of -12.43% beat Achieve Life Sciences' return on equity.
95.9% of XOMA Royalty shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 9.1% of XOMA Royalty shares are held by insiders. Comparatively, 3.0% of Achieve Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
XOMA Royalty has higher revenue and earnings than Achieve Life Sciences. XOMA Royalty is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
XOMA Royalty beats Achieve Life Sciences on 8 of the 15 factors compared between the two stocks.
Get Achieve Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Achieve Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ACHV) was last updated on 7/5/2025 by MarketBeat.com Staff
